Good morning :)
Place Order
Add to Watchlist

Mankind Pharma Ltd

MANKIND Share Price

2,193.200.59% (-13.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹91,077 cr, stock is ranked 120

Stock is 2.46x as volatile as Nifty

MANKIND Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹91,077 cr, stock is ranked 120

Stock is 2.46x as volatile as Nifty

MANKIND Performance & Key Metrics

MANKIND Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
52.026.25
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.945.830.58%

MANKIND Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
81%
Analysts have suggested that investors can buy this stock

from 16 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

MANKIND Company Profile

Mankind Pharma Ltd develops and markets a wide range of pharmaceutical formulations across various therapeutic areas, including anti-infectives and cardiovascular products.

Investor Presentation

View older View older 

Nov 6, 2025

PDF
View Older Presentations

MANKIND Similar Stocks (Peers)

Compare with peers Compare with peers 

MANKIND Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
Compare with Peers

MANKIND Sentiment Analysis

MANKIND Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

MANKIND Stock Summary · November 2025

Mankind Pharma demonstrated resilience with a 21% year-on-year revenue increase in Q2 FY '26, driven by strong domestic growth, particularly in chronic segments, despite facing challenges such as supply chain disruptions and a decline in gross margins. The company is strategically enhancing its market position through facility expansions and improved prescriber penetration, while also investing in R&D to foster innovation. However, rising employee costs and integration challenges have pressured profitability, leading to a 21.3% decline in profit after tax. Despite these hurdles, management remains optimistic about achieving double-digit growth in the domestic formulation business, emphasizing a commitment to long-term transformation and operational efficiency.

MANKIND Stock Growth Drivers
MANKIND Stock Growth Drivers
8
  • Strong Revenue Growth

    Mankind Pharma has reported significant revenue growth, with a 21% year-on-year increase in Q2 FY

  • Improved Market Position

    The company has achieved a notable improvement in its market position, with its chronic share

MANKIND Stock Challenges
MANKIND Stock Challenges
5
  • Declining Revenue and Profitability

    Mankind Pharma's OTC business revenue declined by 3% year-on-year, attributed to supply chain disruptions and

  • Increased Costs and Financial Pressures

    The company has faced rising employee costs due to increased headcount and restructuring efforts, leading

MANKIND Forecast

MANKIND Forecasts

Price

Revenue

Earnings

MANKIND

MANKIND

Income

Balance Sheet

Cash Flow

MANKIND Income Statement

MANKIND Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 16.34%, vs industry avg of 10.03%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 2.38% to 3.03%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 14.08%, vs industry avg of 20.02%

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue5,987.196,397.067,992.048,890.4210,556.8512,761.0014,063.65
Raw Materialssubtract1,888.532,028.002,871.322,622.903,252.143,672.0410,282.73
Power & Fuel Costsubtract79.9682.53103.13108.96125.16149.49
Employee Costsubtract1,335.531,415.781,620.591,918.472,260.602,692.37
Selling & Administrative Expensessubtract885.851,086.441,410.011,616.921,870.542,447.80
Operating & Other expensessubtract237.29-47.44-214.04580.25236.83225.27
Depreciation/Amortizationsubtract99.06118.97166.62325.92378.42621.22858.54
Interest & Other Itemssubtract23.2421.1659.8045.7634.24431.95751.80
Taxes & Other Itemssubtract407.31426.19541.12389.39486.02529.90419.75
EPS25.7231.5935.7832.0047.7548.9742.44
DPS0.007.600.000.000.000.001.00
Payout ratio0.000.240.000.000.000.000.02

MANKIND Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

Nov 6PDF
Jul 31PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 21PDF
Jan 23PDF
Nov 5PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 2PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
 

MANKIND Stock Peers

MANKIND Past Performance & Peer Comparison

MANKIND Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Mankind Pharma Ltd45.756.25
Sun Pharmaceutical Industries Ltd39.926.020.88%
Torrent Pharmaceuticals Ltd67.2116.920.84%
Cipla Ltd23.303.931.05%

MANKIND Stock Price Comparison

Compare MANKIND with any stock or ETF
Compare MANKIND with any stock or ETF
MANKIND
Loading...

MANKIND Holdings

MANKIND Shareholdings

MANKIND Promoter Holdings Trend

MANKIND Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

MANKIND Institutional Holdings Trend

MANKIND Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

MANKIND Shareholding Pattern

MANKIND Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.67%7.78%4.14%12.84%2.57%

Dec 2024

Mar 2025

Jun 2025

Sep 2025

MANKIND Shareholding History

MANKIND Shareholding History

JunSepDec '24MarJunSep11.58%12.37%13.34%12.92%13.07%12.84%

Mutual Funds Invested in MANKIND

Mutual Funds Invested in MANKIND

No mutual funds holding trends are available

Top 5 Mutual Funds holding Mankind Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.0661%1.78%-0.20%25/49 (-2)
0.6731%1.54%0.30%21/54 (+6)
0.3484%0.90%-0.07%35/105 (-3)

Compare 3-month MF holding change on Screener

MANKIND Insider Trades & Bulk Stock Deals

MANKIND Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing MANKIND stock

smallcases containing MANKIND stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Mankind Pharma Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

MANKIND's Wtg.
11.12%
11.12%
CAGR
18.58%

MANKIND Events

MANKIND Events

MANKIND Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

MANKIND Dividend Trend

No dividend trend available

MANKIND Upcoming Dividends

MANKIND Upcoming Dividends

No upcoming dividends are available

MANKIND Past Dividends

MANKIND Past Dividends

Cash Dividend

Ex DateEx DateAug 8, 2025

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Aug 8, 2025

MANKIND Stock News & Opinions

MANKIND Stock News & Opinions

Corporate
Mankind Pharma allots 46,582 equity shares under ESOP

Mankind Pharma has allotted 46,582 equity shares under ESOP on 26 November 2025. With this allotment, the paid up equity share capital has increased to 41,28,05,072 equity shares having face value of Re 1/- each. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Mankind Pharma Ltd eases for fifth straight session

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2222.3, down 0.64% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 25609.05. The Sensex is at 83614.62, up 0.09%.Mankind Pharma Ltd has eased around 9.02% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 0.57% in last one month and is currently quoting at 22379.85, down 0.22% on the day. The volume in the stock stood at 2.28 lakh shares today, compared to the daily average of 3.64 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2231.5, down 0.72% on the day. Mankind Pharma Ltd tumbled 15.25% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.The PE of the stock is 55.39 based on TTM earnings ending September 25.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Mankind Pharma consolidated net profit declines 21.72% in the September 2025 quarter

Net profit of Mankind Pharma declined 21.72% to Rs 511.51 crore in the quarter ended September 2025 as against Rs 653.47 crore during the previous quarter ended September 2024. Sales rose 20.77% to Rs 3697.16 crore in the quarter ended September 2025 as against Rs 3061.43 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3697.163061.43 21 OPM %24.9227.67 - PBDT845.84951.72 -11 PBT624.02851.23 -27 NP511.51653.47 -22 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Mankind Pharma receives affirmation in credit ratings from CRISIL

Mankind Pharma has received reaffirmation in credit ratings from CRISIL at CRISIL AA+/ Stable / CRISIL A1+. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Mankind Pharma schedules board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma Ltd eases for fifth straight session

Mankind Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 2496.5, down 1.18% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24755.4. The Sensex is at 80723.46, down 0.54%.Mankind Pharma Ltd has gained around 0.91% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 1.23% in last one month and is currently quoting at 21977.7, down 1.99% on the day. The volume in the stock stood at 2.14 lakh shares today, compared to the daily average of 3.32 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2494.1, down 1.24% on the day. Mankind Pharma Ltd tumbled 3.68% in last one year as compared to a 5.44% slide in NIFTY and a 8.41% fall in the Nifty Pharma index.The PE of the stock is 57.48 based on TTM earnings ending June 25.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Mankind Pharma allots 29,742 equity shares under ESOP

Mankind Pharma has allotted 29,742 equity shares of face value of Re. 1/- each of the Company to the eligible employees who have exercised their options pursuant to the ESOP Plan. These shares shall rank pari-passu with the existing equity shares of the Company. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from 41,27,28,748 Equity Shares to 41,27,58,490 Equity Shares having face value of Re. 1/- each.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Mankind Pharma Ltd soars 2.96%, Gains for third straight session

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2580.7, up 2.96% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 25125.75. The Sensex is at 82155.87, up 0.36%. Mankind Pharma Ltd has dropped around 3.36% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has dropped around 0.59% in last one month and is currently quoting at 21969.5, up 0.94% on the day. The volume in the stock stood at 8.44 lakh shares today, compared to the daily average of 5.46 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2586.9, up 2.94% on the day. Mankind Pharma Ltd is up 11.26% in last one year as compared to a 1.27% gain in NIFTY and a 1.65% gain in the Nifty Pharma index.The PE of the stock is 57.14 based on TTM earnings ending June 25.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 2435.4, down 1.28% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24473.2. The Sensex is at 80206.91, up 0.44%.Mankind Pharma Ltd has lost around 9.68% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 3.79% in last one month and is currently quoting at 21402.15, up 0.75% on the day. The volume in the stock stood at 2.26 lakh shares today, compared to the daily average of 6.22 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2451.9, down 0.9% on the day. Mankind Pharma Ltd jumped 13.17% in last one year as compared to a 0.52% rally in NIFTY and a 2.9% fall in the Nifty Pharma index.The PE of the stock is 56.23 based on TTM earnings ending June 25.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Mankind Pharma consolidated net profit declines 18.30% in the June 2025 quarter

Net profit of Mankind Pharma declined 18.30% to Rs 438.32 crore in the quarter ended June 2025 as against Rs 536.49 crore during the previous quarter ended June 2024. Sales rose 24.50% to Rs 3570.35 crore in the quarter ended June 2025 as against Rs 2867.85 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales3570.352867.85 24 OPM %23.7223.42 - PBDT759.17764.03 -1 PBT540.49661.34 -18 NP438.32536.49 -18 Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Mankind Pharma Ltd (MANKIND) today?

    The share price of MANKIND as on 5th December 2025 is ₹2193.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Mankind Pharma Ltd (MANKIND) share?

    The past returns of Mankind Pharma Ltd (MANKIND) share are
    • Past 1 week: -2.48%
    • Past 1 month: -7.95%
    • Past 3 months: -14.11%
    • Past 6 months: -5.95%
    • Past 1 year: -15.02%
    • Past 3 years: N/A%
    • Past 5 years: 55.12%

  3. What are the peers or stocks similar to Mankind Pharma Ltd (MANKIND)?
  4. What is the market cap of Mankind Pharma Ltd (MANKIND) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd (MANKIND) is ₹91077.18 Cr as of 5th December 2025.

  5. What is the 52 week high and low of Mankind Pharma Ltd (MANKIND) share?

    The 52-week high of Mankind Pharma Ltd (MANKIND) is ₹3054.80 and the 52-week low is ₹2115.10.

  6. What is the PE and PB ratio of Mankind Pharma Ltd (MANKIND) stock?

    The P/E (price-to-earnings) ratio of Mankind Pharma Ltd (MANKIND) is 45.75. The P/B (price-to-book) ratio is 6.25.

  7. Which sector does Mankind Pharma Ltd (MANKIND) belong to?

    Mankind Pharma Ltd (MANKIND) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Mankind Pharma Ltd (MANKIND) shares?

    You can directly buy Mankind Pharma Ltd (MANKIND) shares on Tickertape. Simply sign up, connect your demat account and place your order.